Buspirone Dosing Recommendations
For adults with generalized anxiety disorder, start buspirone at 7.5 mg twice daily (15 mg/day total), increase by 5 mg/day every 2-3 days as needed, with a typical target dose of 15-30 mg/day divided twice or three times daily, and a maximum of 60 mg/day. 1
Adult Dosing
Initial Dosing
- Starting dose: 7.5 mg twice daily (BID) or 5 mg three times daily (TID)
- Both BID and TID regimens show equivalent efficacy and safety 2
- The drug is rapidly absorbed with peak levels occurring within 40-90 minutes 1
Titration Schedule
- Increase by 5 mg/day every 2-3 days based on response
- Target therapeutic range: 15-30 mg/day divided into 2-3 doses 1, 2
- Maximum dose: 60 mg/day per FDA labeling 1
- Steady-state is reached after 3-5 days of dosing 3
Food Effects
Important caveat: Taking buspirone with food increases drug exposure significantly—AUC and Cmax increase by 84% and 116% respectively 1. For consistent dosing, administer either always with food or always without food.
Special Populations
Elderly Patients (≥65 years)
No dose adjustment is required for elderly patients. 1
- Pharmacokinetic studies show no age-related differences in drug exposure 1
- A large study of 6,632 patients (605 elderly, mean age 70.8 years) demonstrated similar safety and efficacy profiles compared to younger patients 4
- Elderly patients achieved anxiety relief at mean doses of 18 mg/day, similar to younger adults 5
- The standard starting dose of 15 mg/day (7.5 mg BID) is appropriate 4
Hepatic Impairment
Buspirone is contraindicated in severe hepatic impairment. 1
- In hepatic impairment, steady-state AUC increases 13-fold compared to healthy subjects 1
- Half-life doubles in hepatic impairment 6
- For moderate hepatic impairment: Reduce dose substantially or avoid use; if used, start at the lowest possible dose (5 mg BID) with careful monitoring 3
- The FDA label explicitly states buspirone administration "cannot be recommended" in severe hepatic impairment 1
Renal Impairment
Buspirone is contraindicated in severe renal impairment. 1
- In renal impairment (CrCl 10-70 mL/min), steady-state AUC increases 4-fold 1
- For moderate renal impairment: Reduce dose or use with caution; consider starting at 5 mg BID with close monitoring 3
- Severe renal impairment is not recommended per FDA labeling 1
Pediatric Dosing (Under 18 Years)
Buspirone is NOT recommended for pediatric patients with generalized anxiety disorder. 1
- Two placebo-controlled trials in 559 pediatric patients (ages 6-17) studied doses of 7.5-30 mg BID (15-60 mg/day)
- No significant differences between buspirone and placebo were found for GAD symptoms 1
- Pharmacokinetic studies show equal or higher plasma exposure in pediatric patients compared to adults for identical doses 1
- Safety profile was acceptable, but lack of efficacy precludes routine use
Key Clinical Considerations
Onset of Action
- Unlike benzodiazepines, buspirone requires 1-2 weeks for initial anxiolytic effects
- Full therapeutic benefit may take 3-4 weeks 7
- Patients should be counseled about delayed onset to prevent premature discontinuation
Drug Interactions
- CYP3A4 inhibitors (verapamil, diltiazem, erythromycin, itraconazole) substantially increase buspirone levels—reduce buspirone dose 6
- CYP3A4 inducers (rifampin) decrease buspirone levels nearly 10-fold—may need dose increase 6
- Cimetidine has minimal effect on buspirone exposure 1
Laboratory Interference
Critical pitfall: Discontinue buspirone at least 48 hours before urine catecholamine testing, as it interferes with metanephrine assays and can cause false-positive results for pheochromocytoma 1